Research programme: anti-CMV monoclonal antibodies - Mitsubishi Tanabe Pharma
Latest Information Update: 26 May 2010
Price :
$50 *
At a glance
- Originator Mitsubishi Pharma Corporation
- Class Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Cytomegalovirus infections in Japan (unspecified route)
- 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
- 21 Mar 2006 The programme is available for licensing (http://www.micusa.com)